Zobrazeno 1 - 10
of 606
pro vyhledávání: '"April W. Armstrong"'
Autor:
April W. Armstrong, Peter Foley, Yan Liu, Megan Miller, Rachel E. Teneralli, Anthony Bewley, Kenneth B. Gordon, Kim A. Papp, Chenglong Han
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2577-2589 (2024)
Abstract Introduction Treating plaque psoriasis (PsO) with guselkumab (GUS) promotes skin clearance and is associated with improvements in health-related quality of life (HRQoL), anxiety, and depression. It is unclear whether improvements in patient-
Externí odkaz:
https://doaj.org/article/2e1fbdbdc341498ebebba1f697824c23
Autor:
April W. Armstrong, H. Chih-Ho Hong, Brian M. Calimlim, Marric G. Buessing, Marjorie M. Crowell, Jonathan I. Silverberg
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 9, Pp 2457-2465 (2024)
Abstract Introduction Efficacy of upadacitinib has been assessed in trials including Measure Up 1 (NCT03569293), Measure Up 2 (NCT03607422), and Heads Up (NCT03738397). Measure Up 1 and 2 assessed efficacy of upadacitinib 30 mg and upadacitinib 15 mg
Externí odkaz:
https://doaj.org/article/c50f79e2bc6f4b5e8459d5588f42735c
Autor:
April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 8, Pp 2235-2248 (2024)
Abstract Introduction Deucravacitinib, a novel, oral, selective allosteric tyrosine kinase 2 inhibitor, demonstrated superiority versus placebo and apremilast in the POETYK PSO-1 and PSO-2 studies. We describe patient-reported outcomes with deucravac
Externí odkaz:
https://doaj.org/article/eb30f9d6f1ac4e2b804fb11e94392dce
Autor:
April W. Armstrong, Andrew F. Alexis, Andrew Blauvelt, Jonathan I. Silverberg, Claire Feeney, Mark Levenberg, Gary Chan, Fan Zhang, Luke Fostvedt
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1849-1861 (2024)
Abstract Introduction Early prediction of abrocitinib efficacy in atopic dermatitis (AD) could help identify candidates for an early dose increase. A predictive model determined week 12 efficacy based on week 4 responses in patients receiving abrocit
Externí odkaz:
https://doaj.org/article/4fcba376017f4075bfd6d2381581d150
Autor:
April W. Armstrong, Sang Hee Park, Vardhaman Patel, Pierre Nicolas, Wei-Jhih Wang, Matthew J. Colombo, Viktor Chirikov
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 7, Pp 1891-1899 (2024)
Abstract Introduction Deucravacitinib demonstrated superior efficacy to apremilast in patients with moderate to severe plaque psoriasis in the POETYK PSO-1 and PSO-2 clinical trials. In the study reported here, we aimed to determine the overall 52-we
Externí odkaz:
https://doaj.org/article/1aec112419374b6eb1dbe535de388b5c
Autor:
April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1615-1631 (2024)
Abstract Introduction Skin involvement in patients with psoriatic arthritis (PsA) worsens the severity and burden of disease. Ixekizumab (IXE), a selective interleukin (IL)-17A antagonist, was compared to placebo (PBO) in the SPIRIT-P1 (NCT01695239)
Externí odkaz:
https://doaj.org/article/3d639bca47a94f48a215a9ee1b30d788
Autor:
Mark G. Lebwohl, John Y. Koo, April W. Armstrong, Bruce E. Strober, George M. Martin, Nicole N. Rawnsley, Earl L. Goehring, Abby A. Jacobson
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 5, Pp 1349-1357 (2024)
Abstract Introduction Brodalumab is a human interleukin-17 receptor A antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond o
Externí odkaz:
https://doaj.org/article/4d96df29b9fb43bc9db5f5236b669fdf
Autor:
Hannah Tolson, Robin Kikuchi, Rebecca K. Yamamoto, Kaviyon Sadrolashrafi, Lily Guo, Audrey Hao, Sara Bilimoria, Danielle Yee, April W. Armstrong
Publikováno v:
Skin Health and Disease, Vol 4, Iss 5, Pp n/a-n/a (2024)
Abstract Background Oral antibiotics are a mainstay of treatment for hidradenitis suppurativa (HS) primarily due to their anti‐inflammatory and anti‐microbial properties. Because antibiotics are frequently prescribed to treat HS, concerns exist r
Externí odkaz:
https://doaj.org/article/0dd562e5580247ff913a7e1caed0866b
Autor:
April W. Armstrong, Elisabeth Riedl, Patrick M. Brunner, Stefano Piaserico, Willie I. Visser, Natalie Haustrup, Bruce W. Konicek, Zbigniew Kadziola, Mercedes Nunez, Alan Brnabic, Christopher Schuster
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Despite the abundance of data concerning biologic treatments for patients with psoriasis, clinicians are often challenged with discerning the optimal treatment for each patient. To inform this selection, this study explored whether a patient’s base
Externí odkaz:
https://doaj.org/article/d5fdfe1fe6a64d17866ff3ddbaaf263a
Autor:
Neil J. Korman, Richard B. Warren, Jerry Bagel, April W. Armstrong, Melinda Gooderham, Bruce Strober, Diamant Thaçi, Akimichi Morita, Shinichi Imafuku, Peter Foley, Howard Sofen, Min Zheng, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Andrew Blauvelt
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis ev
Externí odkaz:
https://doaj.org/article/565ff6e9db3f40f3996833c3bba76026